Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy

Biomaterials

Volumn 35, Issue 22, 2014, Pages 5965-5976

  Zhu, Qiao ling ^a   Zhou, Yi ^a,b   Guan, Min ^a,c   Zhou, Xiao feng ^a   Yang, Shu di ^a   Liu, Yang ^a   Chen, Wei liang ^a   Zhang, Chun ge ^a   Yuan, Zhi qiang ^a   Liu, Chun ^d   Zhu, Ai jun ^a   Zhang, Xue nong ^a  

^a SOOCHOW UNIVERSITY   (China)

^b WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d SUZHOU MUNICIPAL HOSPITAL   (China)

Author keywords

Co delivery; Low density lipoprotein; Multidrug resistance; Nanoparticles; SiRNA; Tumor targeting therapy

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; CELL PROLIFERATION; CHITOSAN; CONTROLLED DRUG DELIVERY; FLUORESCENCE MICROSCOPY; LIPOPROTEINS; MACROPHAGES; MULTILAYERS; NANOPARTICLES; PARTICLE SIZE; POLYMERASE CHAIN REACTION; TRANSCRIPTION; TUMORS;

CO DELIVERIES; LOW DENSITY LIPOPROTEINS; MULTIDRUG RESISTANCE; SIRNA; TUMOR TARGETING;

TARGETED DRUG DELIVERY;

CHITOSAN; DOXORUBICIN; LOW DENSITY LIPOPROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; SMALL INTERFERING RNA; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; MULTIDRUG RESISTANCE PROTEIN; N-SUCCINYL-CHITOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DENSITY GRADIENT CENTRIFUGATION; DRUG ACCUMULATION; DRUG RELEASE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE SILENCING; HEPATOCYTE TARGETED THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROMETRY; LIPID MONOLAYER; MACROPHAGE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PARTICLE SIZE; PERITONEUM MACROPHAGE; PH; PHAGOCYTOSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RIBONUCLEASE PROTECTION ASSAY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; LIVER; LIVER NEOPLASMS; METABOLISM; MULTIDRUG RESISTANCE; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHITOSAN; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; FEMALE; HEP G2 CELLS; HUMANS; LIPOPROTEINS, LDL; LIVER; LIVER NEOPLASMS; MICE; MICE, NUDE; NANOPARTICLES; P-GLYCOPROTEIN; RNA, SMALL INTERFERING;

EID: 84899988545     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.088     Document Type: Article

References (31)

1. Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627.
2. Zhao Z.X., Gao S.Y., Wang J.C., Chen C.J., Zhao E.Y., Hou W.J., et al. Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine (R15) triblock copolymer for siRNA delivery. Biomaterials 2012, 33:6793-6807.
3. Meng H., Liong M., Xia T., Li Z.X., Ji Z.X., Zink J.I., et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS nano 2010, 4:4539-4550.
4. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007, 8:173-184.
5. Kesharwani P., Gajbhiye V., Jain N.K. Areview of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012, 33:7138-7150.
6. Heyes J., Palmer L., Bremner K., MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. JControl Release 2005, 107:276-287.
7. Aliabadi H.M., Landry B., Sun C., Tang T., Uludag H. Supramolecular assemblies in functional siRNA delivery: where do we stand?. Biomaterials 2012, 33:2546-2569.
8. Shukla R.S., Tai W., Mahato R., Jin W., Cheng K. Development of streptavidin-based nanocomplex for siRNA delivery. Mol Pharm 2013, 10:4534-4545.
9. Patil Y., Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm 2009, 367:195-203.
10. Kim H.K., Davaa E., Myung C.S., Park J.S. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm 2010, 392:141-147.
11. Mao S.R., Sun W., Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 2010, 62:12-27.
12. Moghimi S.M., Symonds P., Murray J.C., Hunter A.C., Debska G., Szewczyk A. Atwo-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 2005, 11:990-995.
13. Liu Y.K., Lin Y.L., Chen C.H. Aunique and potent protein binding nature of liposome containing polyethylenimine and polyethylene glycol: a nondisplaceable property. Biotechnol Bioeng 2011, 108:1318-1327.
14. Verdurmen W.P., Brock R. Biological responses towards cationic peptides and drug carriers. Trends Pharm Sci 2011, 32:116-124.
15. Kader A., Pater A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. JControl Release 2002, 80:29-44.
16. Nikanjam M., Gibbs A.R., Hunt C.A., Budinger T.F., Forte T.M. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle. JControl Release 2007, 124:163-171.
17. Brown M.S., Herz J., Goldstein J.L. LDL-receptor structure. Calcium cages, acid baths and recycling receptors. Nature 1997, 388:629-630.
18. Van Berkel T.J.C. Drug targeting: application of endogenous carriers for site specific delivery of drug. JControl Release 1993, 24:145-155.
19. Huntosova V., Buzova D., Petrovajova D., Kasak P., Nadova Z., Jancura D., et al. Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells. Int J Pharm 2012, 436:463-471.
20. Zheng G., Chen J., Li H., Glickson J.D. Rerouting lipoprotein nanoparticles to selected alternate receptors for targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci U S A 2005, 102:17757-17762.
21. Iwanik M.J., Shaw K.V., Ledwith B.J., Yanovich S., Shaw J.M. Preparation and interaction of a low-density lipoprotein: Daunomycin complex with P388 leukemic cells. Cancer Res 1984, 44:1206-1215.
22. Hou Z.Q., Han J., Zhan C.M., Zhou C.X., Hu Q., Zhang Q.Q. Synthesis and evaluation of N-succinyl-chitosan nanoparticles toward local hydroxycamptothecin delivery. Carbohydr Polym 2010, 81:765-768.
23. Guan M., Zhou Y., Zhu Q.L., Liu Y., Bei Y.Y., Zhang X.N., et al. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy. Nanomedicine 2012, 8:1172-1181.
24. Yang Z.Q., Xu J., Pan P., Zhang X.N. Preparation of an alternative freeze-dried pH-sensitive cyclosporine A nanoparticle formulation and its pharmacokinetic profile in rats. Pharmazie 2008, 63:26-31.
25. Sambrano G.R., Steinberg D. Recognition of oxidatively damaged and apoptotic cells by an oxidized low density lipoprotein receptor on mouse peritoneal macrophages: role of membrane phosphatidylserine. Proc Natl Acad Sci U S A 1995, 92:1396-1400.
26. Tseng Y.C., Mozumdar S., Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 2009, 61:721-731.
27. Illum L., Davis S.S., Muller R.H., Mak E., West P. The organ distribiton and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer-poloxamine 908. Life Sci 1987, 40:367-374.
28. Zhang W.L., Gu X., Bai H., Yang R.H., Dong C.D., Liu J.P. Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. Int J Pharm 2010, 391:313-321.
29. Shimada K., Miyagishima A., Sadzuka Y., Nozawa Y., Mochizuki Y., Ohshima H., et al. Determination of the thickness of the fixed aqueous layer around polyethyleneglycol-coated liposomes. JDrug Target 1995, 3:283-289.
30. null cells. Proc Natl Acad Sci U S A 2007, 104:13744-13749.
31. Son Y.J., Jang J.S., Cho Y.W., Chung H., Park R.W., Kwon I.C., et al. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. JControl Release 2003, 91:135-145.